Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28458797)

Published in Infect Dis Rep on March 30, 2017

Authors

Ursula Theuretzbacher1, Christine Årdal2, Stephan Harbarth3

Author Affiliations

1: Center for Anti-Infective Agents, Vienna, Austria.
2: Norwegian Institute of Public Health, Oslo, Norway.
3: Infection Control Program and Division of Infectious Diseases, University of Geneva Hospitals and Medical Faculty, Geneva, Switzerland.

Articles cited by this

Antibiotic resistance-the need for global solutions. Lancet Infect Dis (2013) 15.01

Challenges of antibacterial discovery. Clin Microbiol Rev (2011) 3.94

Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ (2016) 2.01

Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. Lancet Infect Dis (2015) 1.75

Understanding the mechanisms and drivers of antimicrobial resistance. Lancet (2015) 1.52

The cost of drug development: a systematic review. Health Policy (2011) 1.37

Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis (2016) 1.27

Medicare and Medicaid Programs; Reform of Requirements for Long-Term Care Facilities. Final rule. Fed Regist (2016) 1.19

Antibiotic effectiveness: balancing conservation against innovation. Science (2014) 1.12

Control of fluoroquinolone resistance through successful regulation, Australia. Emerg Infect Dis (2012) 1.11

Antibiotic research and development: business as usual? J Antimicrob Chemother (2015) 0.99

The negative impact of antibiotic resistance. Clin Microbiol Infect (2015) 0.90

Closing the divide: the Harvard Global Equity Initiative-Lancet Commission on global access to pain control and palliative care. Lancet (2015) 0.90

Antibiotics in Wastewater of a Rural and an Urban Hospital before and after Wastewater Treatment, and the Relationship with Antibiotic Use-A One Year Study from Vietnam. Int J Environ Res Public Health (2016) 0.83

Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov (2016) 0.80

Australian Group on Antimicrobial Resistance Community-onset Gram-negative Surveillance Program annual report, 2010. Commun Dis Intell Q Rep (2013) 0.78